David Ridley

David Ridley

Senior Editor

Conventry, UK

David's coverage specializes in OTC medicines, dietary supplements and self-care medical devices. David is interested in regulatory gray areas such as the borderlines between medicines, supplements and medical devices, as well as botanical ingredients. David also regularly speaks to industry leaders and experts about the latest trends to deliver crucial market intelligence to HBW Insight readers, and co-hosts the Over the Counter podcast. In his spare time, David spends time in his allotment garden, reading/watching science fiction and worrying about climate change.

Latest from David Ridley

Haleon Launches ‘Prescription Strength’ Hayfever Remedy In The UK

Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”

Over The Counter: The Challenge Of Innovating In A Changing OTC Industry With AdverCheck’s James Walmsley

Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.

Germans Favor Bricks-And-Mortar Pharmacy Over Mail-Order For OTCs

Almost two thirds (62%) of respondents to an online survey said they would rather buy non-prescription medicines in a local pharmacy than via a mail-order pharmacy, Pharma Deutschland reports.

PAGB Launches E-Learning Platform Including CBD ‘Deep Dive’

UK industry association is offering online courses on subjects ranging from UK medicines regulations basics to deep dives on complex topics such as CBD.

Haleon Launches 24 Hour Voltarol Medicated Plaster In The UK

Voltarol One A Day Muscle Pain Relief Medicated Plaster provides up to 24 hours relief from pain and inflammation, according to manufacturer Haleon.

Over The Counter: Why OTC Firms Should Care About Rx Advertising, With AdverCheck’s James Walmsley

HBW Insight speaks to AdverCheck managing director James Walmsley about the rise of direct-to-consumer prescription drugs marketing in the UK, and its impact on the consumer healthcare industry.